Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Offers affordable, high-quality solutions for diabetes care
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
The trademark rights for these brands will be transferred to Lupin by March next year.
Subscribe To Our Newsletter & Stay Updated
